Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors

Yuji Ikari; Yuya Matsue; Sho Torii; Misaki Hasegawa; Kazuki Aihara; Shunsuke Kuroda; Takahide Sano; Takeshi Kitai; Taishi Yonetsu; Shun Kohsaka; Takuya Kishi; Issei Komuro; Ken-ichi Hirata; Koichi Node; Shingo Matsumoto

doi:10.1253/circj.CJ-21-0087

Rapid Communications

Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors

Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken-ichi Hirata, Koichi Node, Shingo Matsumoto

Author information

Yuji Ikari
Department of Cardiology, Tokai University School of Medicine [Japan]
Yuya Matsue
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine [Japan]
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine [Japan]
Sho Torii
Department of Cardiology, Tokai University School of Medicine [Japan]
Misaki Hasegawa
Department of Cardiology, Tokai University School of Medicine [Japan]
Kazuki Aihara
Department of Cardiology, Tokai University School of Medicine [Japan]
Shunsuke Kuroda
Department of Cardiology, Kameda Medical Center [Japan]
Department of Cardiovascular Medicine, Cleveland Clinic [United States]
Takahide Sano
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine [Japan]
Department of Cardiology, Ebara Hospital [Japan]
Takeshi Kitai
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital [Japan]
Taishi Yonetsu
Department of Interventional Cardiology, Tokyo Medical and Dental University [Japan]
Shun Kohsaka
Department of Cardiology, Keio University School of Medicine [Japan]
Takuya Kishi
Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare [Japan]
Issei Komuro
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo [Japan]
Ken-ichi Hirata
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine [Japan]
Koichi Node
Department of Cardiovascular Medicine, Saga University [Japan]
Shingo Matsumoto
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine [Japan]

Keywords: Cardiovascular risk factors, Coronavirus disease 2019 (COVID-19), Statin

JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2021 Volume 85 Issue 6 Pages 939-943

DOI https://doi.org/10.1253/circj.CJ-21-0087

Browse “Advance online publication” version

Details

Abstract

Background:Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).

Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.

Conclusions:This study suggests the potential benefits of statins use against COVID-19.

Corresponding author

Register with J-STAGE for free!